Tafolecimab (PCSK9) - Research Grade Biosimilar

GPRC5D / CD3 bispecific antibody is used to treat multiple myeloma. The bispecific antibody is commonly known as tafolecimab. It is constructed using the Duobody technology authorized by Genmab. The heavy chain of anti-CD3 antibody introduced F405L and R409K to construct the double antibody. S228P, F234A, and L235A mutations were simultaneously introduced into the IgG4 constant region.

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.